Wala Ben Kridis
1* 
, Sonda Masmoudi
1, Salma Ben Charfeddine
2, Afef Khanfir
11 Department of Medical Oncology, Habib Bourguiba Hospital, University of Sfax, Tunisia
2 Department of Cardiology, Hedi Chaker Hospital, University of Sfax, Tunisia
*Corresponding Author: Corresponding Author:Wala Ben Kridis, MD; Department of oncology, Habib Bourguiba Hospital, Sfax 3029, Tunisia. Tel:+21694492526, E-mail: , Email:
walabenkridis@yahoo.fr
Abstract
Common cardiovascular toxicities of sunitinib mainly include hypertension, QT prolongation, left ventricular dysfunction (LVD) and less frequently, congestive heart failure (CHF). Here, we report the case of a 67-year-old woman who developed heart failure after 24 months of sunitinib. Our case highlights the importance of strict and regular cardiovascular monitoring during sunitinib. It also shows that the reintroduction of sunitinib with maintaining heart failure treatment can be safe. The exact mechanisms of this cardiotoxicity have not been understood. There is no protective therapy available. Therefore, further investigations are needed in these areas. Medical specialists who prescribe and treat patients with sunitinib should be aware of the possible occurrence of these conditions and perform regular checkup of sunitinib-treated patients.